1.
Simpson E, Merola J, Silverberg J, Zachariae R, Olsen R, Wollenberg A. Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. J of Skin [Internet]. 2021 Jan. 1 [cited 2024 Jul. 4];5(1):s11. Available from: https://jofskin.org/33014/index.php/skin/article/view/1164